Technical Analysis for EDSA - Edesa Biotech, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 2.17 | 2.84% | 0.06 |
EDSA closed up 2.84 percent on Friday, November 22, 2024, on 16 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Dec 13
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 2.84% | |
| NR7 | Range Contraction | 2.84% | |
| Narrow Range Bar | Range Contraction | 2.84% | |
| Doji - Bullish? | Reversal | 2.84% | |
| Wide Bands | Range Expansion | 2.84% | |
| Gapped Down | Weakness | 2.84% | |
| Oversold Stochastic | Weakness | 2.84% | |
| Hammer Candlestick | Bullish | -1.36% |
| Alert | Time |
|---|---|
| Possible NR7 | about 13 hours ago |
| 10 DMA Resistance | about 16 hours ago |
| Rose Above Previous Day's High | about 18 hours ago |
| Up 3% | about 18 hours ago |
| Down 1% | about 18 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 12/13/2024
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on efficiently developing innovative treatments that address significant unmet medical needs. Edesa's lead product candidate, EB01, is a novel non-steroidal anti-inflammatory molecule (sPLA2 inhibitor) for the treatment of chronic allergic contact dermatitis which has demonstrated statistically significant improvements in multiple clinical studies. Edesa also intends to expand the utility of its sPLA2 inhibitor technology, which forms the basis for EB01, across multiple indications. The company is based in Toronto, Canada, with U.S. offices in Southern California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Medication Dermatitis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Medication Dermatitis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.46 |
| 52 Week Low | 2.05 |
| Average Volume | 27,885 |
| 200-Day Moving Average | 4.30 |
| 50-Day Moving Average | 3.54 |
| 20-Day Moving Average | 2.59 |
| 10-Day Moving Average | 2.21 |
| Average True Range | 0.24 |
| RSI (14) | 26.47 |
| ADX | 30.46 |
| +DI | 13.21 |
| -DI | 24.68 |
| Chandelier Exit (Long, 3 ATRs) | 3.20 |
| Chandelier Exit (Short, 3 ATRs) | 2.78 |
| Upper Bollinger Bands | 3.51 |
| Lower Bollinger Band | 1.66 |
| Percent B (%b) | 0.28 |
| BandWidth | 71.89 |
| MACD Line | -0.43 |
| MACD Signal Line | -0.44 |
| MACD Histogram | 0.0152 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.37 | ||||
| Resistance 3 (R3) | 2.36 | 2.28 | 2.33 | ||
| Resistance 2 (R2) | 2.28 | 2.23 | 2.29 | 2.32 | |
| Resistance 1 (R1) | 2.23 | 2.20 | 2.26 | 2.24 | 2.31 |
| Pivot Point | 2.15 | 2.15 | 2.17 | 2.16 | 2.15 |
| Support 1 (S1) | 2.10 | 2.10 | 2.13 | 2.11 | 2.03 |
| Support 2 (S2) | 2.02 | 2.07 | 2.03 | 2.02 | |
| Support 3 (S3) | 1.97 | 2.02 | 2.01 | ||
| Support 4 (S4) | 1.98 |
